Navigation Links
Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Date:6/25/2008

t of acne, we intend to advance SL017 PDT for one or more clinical indications," stated Thomas Woo, M.Sc., Vice President for Drug Development of Quest.

The Principal Investigator for Quest's Phase I/II hair removal trial is Dr. Robert Bissonnette, M.D., President of Innovaderm Research in Montreal.

About SL017: SL017 is a proprietary, non-toxic drug that, once applied to a target area and activated by light, is transformed into a potent cytotoxic agent that selectively destroys targeted tissue. Using this process, known as photodynamic therapy (PDT), SL017 can be applied to treat a variety of skin conditions, including hair removal, actinic keratosis and acne. The safety and potential utility of SL017 for the treatment of actinic keratosis has been demonstrated in a Phase I Clinical Study.

About Quest PharmaTech Inc.: Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platform.

"TSX Venture Exchange has neither approved nor disapproved of the

information herein."


'/>"/>
SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email: